Form 8-K - Current report:
SEC Accession No. 0001213900-22-023169
Filing Date
2022-05-02
Accepted
2022-05-02 16:05:45
Documents
12
Period of Report
2022-04-26
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 2.06: Material Impairments

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea159231-8k_nektarthera.htm   iXBRL 8-K 29393
  Complete submission text file 0001213900-22-023169.txt   202547

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20220426.xsd EX-101.SCH 3027
3 XBRL LABEL FILE nktr-20220426_lab.xml EX-101.LAB 34476
4 XBRL PRESENTATION FILE nktr-20220426_pre.xml EX-101.PRE 22591
6 EXTRACTED XBRL INSTANCE DOCUMENT ea159231-8k_nektarthera_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 22881898
SIC: 2834 Pharmaceutical Preparations